Please ensure Javascript is enabled for purposes of website accessibility

CSL Behring and Takeda Pharmaceutical Are Leading a Coalition to Develop a COVID-19 Hyperimmune Therapy

By Brian Orelli, PhD – Apr 8, 2020 at 3:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Six companies will work together to develop a plasma-derived antibody product to fight SARS-CoV-2.

CSL Behring (CSLL.Y -1.45%) and Takeda Pharmaceutical (TAK) are joining forces with four other companies -- Biotest, Bio Products Laboratory, LFB, and Octapharma -- to develop a plasma-derived antibody treatment they hope will prove effective against COVID-19, the disease caused by the novel coronavirus. Rather than compete against each other, the alliance plans to develop one unbranded product.

"Unprecedented times call for bold moves," Julie Kim, president of Takeda's plasma-derived therapies business unit, said of the decision to cooperate on the treatment. "We invite companies and institutions focusing on plasma to support or join our alliance."

Hint, hint, EmergentBiosolutions (EBS 1.01%), which is developing plasma-based drugs of its own.

Patient and doctor behind a sign reading "caution, outbreak alert."

Image source: Getty Images.

Plasma from patients who have recovered from COVID-19 contains antibodies that bind to SARS-CoV-2, the coronavirus that causes the illness. Development of the new product will require a large number of recovered patients to donate plasma, so CSL, Takeda and the other companies are encouraging people who have gotten over the virus to find a plasma collection center where they can donate. That plasma will then be shipped to manufacturing plants where the antibodies can be purified. The Food and Drug Administration is working on a similar plasma-collection initiative in cooperation with the American Red Cross.

Separately, CSL and SAB Biotherapeutics are developing an antibody treatment called SAB-185 that will be fully manufactured, eliminating the need for plasma donors. Those companies hope to start a clinical trial of SAB-185 in COVID-19 patients as early as this summer.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Takeda Pharmaceutical Company Limited Stock Quote
Takeda Pharmaceutical Company Limited
TAK
$12.97 (%)
CSL Limited Stock Quote
CSL Limited
CSLL.Y
$91.25 (-1.45%) $-1.34
Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$20.99 (1.01%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.